Background/Aims: Macrolide antibiotics are effective drugs in chronic bronchiolitis and chronic rhinosinusitis with mucus hypersecretion. However, the mechanism of action is unclear. This study was designed to investigate the effect of azithromycin (AZM; 15-membered) and midecamycin acetate (MDM; 16-membered) on MUC5AC and MUC2 gene expression and secretion from human airway epithelial cells. The effects of the two macrolides on tumor necrosis factor-α (TNF-α) release were also examined. Methods: Confluent NCI-H292 human mucoepidermoid airways epithelial cells were pretreated with AZM or MDM for 2 h and then stimulated with 200 nmol/l phorbol 12-myristate 13-acetate (PMA) for 8 h. The MUC5AC and MUC2 gene expression was measured by real-time quantitative RT-PCR. Total mucin in culture supernatants was measured using enzyme-linked lectin assay. Enzyme-linked immunosorbent assay was used to determine MUC5AC, MUC2 and TNF-α released by the cells. Results: AZM and MDM attenuated PMA-induced MUC5AC and MUC2 gene and protein expression in NCI-H292 cells. They also suppressed PMA-mediated TNF-α in the cells. Conclusion: The present study demonstrates that AZM and MDM suppress the synthesis of mucin and TNF-α from human airway epithelial cells.

Keywords:
Macrolide, Airway epithelial cells, Phorbal 12-myristate 13-acetate, MUC5AC, MUC2
1.
Feldman C, Anderson R: Therapy for pneumococcal bacteremia: monotherapy or combination therapy? Curr Opin Infect Dis 2009;22:137-142.
2.
Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C: Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm 2012;2012:584262.
3.
Kim YD, Cho JS, Kim HS, Song SH: Effect of macrolide on the interleukin-1 β-mediated MUC2/5AC genes expression and mucin secretion in human airway epithelial cells. J Rhinol 2002;9:52-56.
4.
Shimizu T, Shimizu S: Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm 2012;2012:265714.
5.
Cigana C, Assael BM, Melotti P: Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007;51:975-981.
6.
Morikawa K, Zhang J, Nonaka M, Morikawa S: Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002;19:53-59.
7.
Koontongkaew S, Monthanapisut P, Saensuk T: Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression. Prostaglandins Other Lipid Mediat 2010;93:100-108.
8.
Inoue D, Yamaya M, Kubo H, Sasaki T, Hosoda M, Numasaki M, Tomioka Y, Yasuda H, Sekizawa K, Nishimura H, Sasaki H: Mechanisms of mucin production by rhinovirus infection in cultured human airway epithelial cells. Respir Physiol Neurobiol 2006;154:484-499.
9.
Li R, Meng Z: Effects of SO2 derivatives on expressions of MUC5AC and IL-13 in human bronchial epithelial cells. Arch Toxicol 2007;81:867-874.
10.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408.
11.
Hewson CA, Edbrooke MR, Johnston SL: Pma induces the MUC5AC respiratory mucin in human bronchial epithelial cells, via PKC, EGF/TGF-α, Ras/Raf, MEK, ERK and Sp1-dependent mechanisms. J Mol Biol 2004;344:683-695.
12.
Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, Boonla C, Wongkham S: A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007;247:301-308.
13.
Morikawa K, Oseko F, Morikawa S, Iwamoto K: Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994;38:2643-2647.
14.
Van Bambeke F, Tulkens PM: Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001;18(suppl 1):S17-S23.
15.
Kim DY, Takeuchi K, Ishinaga H, Kishioka C, Suzuki S, Basbaum C, Majima Y: Roxithromycin suppresses mucin gene expression in epithelial cells. Pharmacology 2004;72:6-11.
16.
Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y: In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003;168:581-587.
17.
Imamura Y, Yanagihara K, Mizuta Y, Seki M, Ohno H, Higashiyama Y, Miyazaki Y, Tsukamoto K, Hirakata Y, Tomono K, Kadota J, Kohno S: Azithromycin inhibits MUC5AC production induced by the pseudomonas aeruginosa autoinducer N-(3-oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob Agents Chemother 2004;48:3457-3461.
18.
Ishimoto H, Mukae H, Sakamoto N, Amenomori M, Kitazaki T, Imamura Y, Fujita H, Ishii H, Nakayama S, Yanagihara K, Kohno S: Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin. J Antimicrob Chemother 2009;63:109-114.
19.
Theodoropoulos G, Carraway KL: Molecular signaling in the regulation of mucins. J Cell Biochem 2007;102:1103-1116.
20.
Ishinaga H, Takeuchi K, Kishioka C, Suzuki S, Basbaum C, Majima Y: Pranlukast inhibits Nf-κB activation and MUC2 gene expression in cultured human epithelial cells. Pharmacology 2005;73:89-96.
21.
Araujo FG, Slifer TL, Remington JS: Inhibition of secretion of interleukin-1α and tumor necrosis factor alpha by the ketolide antibiotic telithromycin. Antimicrob Agents Chemother 2002;46:3327-3330.
22.
Khan AA, Slifer TR, Araujo FG, Remington JS: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999;11:121-132.
23.
Mazzariol A, Koncan R, Vitali LA, Cornaglia G: Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. J Antimicrob Chemother 2007;59:1171-1176.
24.
Schlegel L, Merad B, Rostane H, Broc V, Bouvet A: In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999. Clin Microbiol Infect 2001;7:362-366.
25.
Sifrim D, Matsuo H, Janssens J, Vantrappen G: Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res 1994;20:121-126.
26.
Cooper MA, Nye K, Andrews JM, Wise R: The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 1990;26:533-538.
27.
Fukaya K, Shomura T, Someya S, Murata K, Umehara K, Kikai S: Absorption, metabolism and excretion of 9,3'-diacetyl midecamycin (MOM) in humans (in Japanese). Chemotherapy (Tokyo) 1981;29:448-457.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.